BillionToOne Company

BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting with developing countries.
Technology: BioTech
Industry: Pregnancy & Nursing
Headquarters: Menlo Park, California, United States
Founded Date: 01-01-2016
Employees Number: 101-250
Funding Status: Late Stage Venture
Investors Number: 23
Total Funding: $212,400,000
Estimated Revenue: $10M to $50M
Last Funding Date: Mar 30, 2022
Last Funding Type: Series C

Visit Website
Register and Claim Ownership